A number of other equities analysts also recently commented on OBSV. Canaccord Genuity Group downgraded shares of ObsEva from a “buy” rating to a “hold” rating and reduced their target price for the stock from $12.00 to $1.00 in a report on Monday, August 1st. Cantor Fitzgerald lowered shares of ObsEva from an “overweight” rating to a “neutral” rating in a report on Thursday, July 28th. Finally, HC Wainwright lowered ObsEva from a “buy” rating to a “neutral” rating in a report on Tuesday, August 30th. Four research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat, ObsEva presently has a consensus rating of “Hold” and an average target price of $10.50.
ObsEva Price Performance
NASDAQ OBSV opened at $0.18 on Wednesday. The company has a market cap of $14.24 million, a PE ratio of -0.23 and a beta of 0.29. The firm’s 50 day moving average price is $0.66 and its 200-day moving average price is $1.24. The company has a debt-to-equity ratio of 1.18, a quick ratio of 2.98 and a current ratio of 2.98. ObsEva has a 52-week low of $0.16 and a 52-week high of $3.35.
Institutional Inflows and Outflows
Hedge funds have recently modified their holdings of the company. Banque Cantonale Vaudoise boosted its holdings in ObsEva by 143.2% during the first quarter. Banque Cantonale Vaudoise now owns 28,868 shares of the company’s stock worth $44,000 after buying an additional 17,000 shares in the last quarter. Virtu Financial LLC acquired a new stake in ObsEva in the first quarter valued at approximately $30,000. XTX Topco Ltd raised its stake in shares of ObsEva by 33.9% during the 1st quarter. XTX Topco Ltd now owns 79,757 shares of the company’s stock worth $120,000 after buying an additional 20,196 shares during the period. Cutter & CO Brokerage Inc. grew its stake in ObsEva by 15.9% in the 1st quarter. Cutter & CO Brokerage Inc. now owns 206,200 shares of the company’s stock valued at $311,000 after acquiring an additional 28,250 shares during the period. Finally, Pictet Asset Management SA increased its holdings in ObsEva by 15.6% in the 2nd quarter. Pictet Asset Management SA now owns 295,399 shares of the company’s stock worth $476,000 after acquiring an additional 39,964 shares in the last quarter. 20.12% of the stock is owned by institutional investors and hedge funds.
ObsEva Company Profile
ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin releasing hormone receptor antagonist that is in Phase III clinical trial for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women.
- Get a free copy of the StockNews.com research report on ObsEva (OBSV)
- Is Five Below Trying to Punch Too High?
- These 3 Reports Will Tell Us Much About the Current Economy
- This Is What To Expect From The S&P 500 Now
- The Two Things You Need To Know About Oracle’s FQ1 Report
- Three Value Stocks For A Volatile Market
Receive News & Ratings for ObsEva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva and related companies with MarketBeat.com's FREE daily email newsletter.